Literature DB >> 30302062

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current Medical Management.

Stephanie L Gold1,2,3,4, Shirley Cohen-Mekelburg1,2,3,4, Yecheskel Schneider1,2,3,4, Adam Steinlauf1,2,3,4.   

Abstract

Despite significant advances in the treatment of luminal inflammatory bowel disease, the treatment of perianal fistulas remains a clinical challenge. Perianal fistulas are traditionally described using the Parks classification based on their relationship to the external and internal anal sphincters. Traditional therapy for perianal fistulas focuses on antibiotics such as metronidazole or ciprofloxacin. However, medical management has expanded over the years to include immunomodulators and, most recently, biologic agents. Newer techniques such as intrafistulous biologic injections are also being explored as potentially effective treatments for patients with fistulizing disease. Here, in the first of a 2-part series on perianal fistulas in patients with Crohn's disease, we discuss the anatomy and classification of perianal fistulas as well as current medical therapies, including antibiotics, immunomodulators, biologic agents, and novel therapeutic agents. The second part of the series will focus on the surgical modalities that are available for patients with perianal fistulas in addition to novel endoscopic techniques and future therapies that are being investigated for the treatment of fistulizing Crohn's disease.

Entities:  

Keywords:  Crohn’s disease; Perianal disease; biologic agents; fistula; immunomodulators

Year:  2018        PMID: 30302062      PMCID: PMC6170888     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  68 in total

1.  Local injection of adalimumab for perianal Crohn's disease: better than infliximab?

Authors:  G Poggioli; S Laureti; F Pierangeli; P Bazzi; M Coscia; L Gentilini; P Gionchetti; F Rizzello
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

2.  A classification of fistula-in-ano.

Authors:  A G Parks; P H Gordon; J D Hardcastle
Journal:  Br J Surg       Date:  1976-01       Impact factor: 6.939

Review 3.  Treatment of fistulizing Crohn's disease.

Authors:  G R Lichtenstein
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

4.  Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.

Authors:  L J Egan; W J Sandborn; W J Tremaine
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

5.  Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study.

Authors:  R L West; C J van der Woude; B E Hansen; R J F Felt-Bersma; A J P van Tilburg; J A G Drapers; E J Kuipers
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

6.  Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease.

Authors:  Y Maeda; S C Ng; P Durdey; C Burt; J Torkington; P Kumar Dhruva Rao; J Mayberry; T Moshkovska; C D Stone; E Carapeti; C J Vaizey
Journal:  Br J Surg       Date:  2010-09       Impact factor: 6.939

7.  [Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study].

Authors:  M U Schneider; G Laudage; I Guggenmoos-Holzmann; J F Riemann
Journal:  Dtsch Med Wochenschr       Date:  1985-11-08       Impact factor: 0.628

8.  Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.

Authors:  Carlos Castaño-Milla; María Chaparro; Cristina Saro; Manuel Barreiro-de Acosta; Ana M García-Albert; Luis Bujanda; María D Martín-Arranz; Daniel Carpio; Fernando Muñoz; Noemí Manceñido; Esther García-Planella; Marta Piqueras; Xavier Calvet; José L Cabriada; Belén Botella; Fernando Bermejo; Javier P Gisbert
Journal:  J Clin Gastroenterol       Date:  2015-01       Impact factor: 3.062

9.  Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Kelvin T Thia; Uma Mahadevan; Brian G Feagan; Cindy Wong; Alan Cockeram; Alain Bitton; Charles N Bernstein; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

10.  Hyperbaric oxygenation in severe perineal Crohn's disease.

Authors:  J F Colombel; D Mathieu; J M Bouault; X Lesage; P Zavadil; P Quandalle; A Cortot
Journal:  Dis Colon Rectum       Date:  1995-06       Impact factor: 4.585

View more
  6 in total

Review 1.  Maneuvering Clinical Pathways for Crohn's Disease.

Authors:  Thomas X Lu; Russell D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2019-04-23

Review 2.  Management of Enterocutaneous Fistula: A Review.

Authors:  Pradeep Ghimire
Journal:  JNMA J Nepal Med Assoc       Date:  2022-01-15       Impact factor: 0.556

3.  Perianal Fistulas in Patients With Crohn's Disease, Part 2: Surgical, Endoscopic, and Future Therapies.

Authors:  Stephanie L Gold; Shirley Cohen-Mekelburg; Yecheskel Schneider; Adam Steinlauf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-09

Review 4.  The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD.

Authors:  Jeroen Geldof; Nusrat Iqbal; Janindra Warusavitarne; Ailsa Hart
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

5.  Ambulatory Surgery for Perianal Crohn's Disease: Study of Feasibility.

Authors:  S Sibio; A Di Giorgio; M Campanelli; S Di Carlo; A Divizia; C Fiorani; R Scaramuzzo; C Arcudi; G Del Vecchio Blanco; L Biancone; G Sica
Journal:  Gastroenterol Res Pract       Date:  2018-12-23       Impact factor: 2.260

6.  Dysbiosis in a canine model of human fistulizing Crohn's disease.

Authors:  Ana Maldonado-Contreras; Lluís Ferrer; Caitlin Cawley; Sarah Crain; Shakti Bhattarai; Juan Toscano; Doyle V Ward; Andrew Hoffman
Journal:  Gut Microbes       Date:  2020-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.